Ropes & Gray LLP has advised Viridian Therapeutics, Inc., and WilmerHale has advised the underwriters. Viridian Therapeutics, Inc. has completed a public offering of 13,138,750 shares...
Viridian Therapeutics Completes $289 Million Public Offering
Viridian Therapeutics Royalty Financing Agreement with DRI Healthcare for up to $300 Million
Ropes & Gray has advised Viridian Therapeutics. Weil and Ballard Spahr have advised DRI Healthcare. Latham & Watkins has advised the lender, Hercules Capital, on the...
Viridian and Kissei Sign Exclusive Licensing Agreement
Ropes & Gray has advised Viridian Therapeutics on the deal. Viridian Therapeutics has entered into an exclusive licensing and collaboration agreement with Kissei Pharmaceutical for the...
Viridian Therapeutics’ $258.8 Million Follow-on Public Offering
Ropes & Gray represented Viridian Therapeutics, Inc. in the offering, and Wilmer Cutler Pickering Hale and Dorr represented the underwriters. Viridian Therapeutics, Inc. (Nasdaq: VRDN), a...
Viridian Therapeutics’ Follow-On Public Offering
Troutman Pepper advised Viridian Therapeutics on the deal. Viridian Therapeutics, In announced that it had issued shares in an underwritten public offering resulting in Viridian receiving approximately...